Urinary kallidinogenase for the treatment of cerebral arterial stenosis

Liandong Zhao,1,2 Ying Zhao,2 Qi Wan,1 Haijun Zhang3 1Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 2Department of Neurology, The Second People’s Hospital of Huai’an and The Affiliated Huai’an Hospital of Xuzhou Medical C...

Full description

Bibliographic Details
Main Authors: Zhao L, Zhao Y, Wan Q, Zhang H
Format: Article
Language:English
Published: Dove Medical Press 2015-10-01
Series:Drug Design, Development and Therapy
Online Access:https://www.dovepress.com/urinary-kallidinogenase-for-the-treatment-of-cerebral-arterial-stenosi-peer-reviewed-article-DDDT
id doaj-e3f32ee024af465f8b1bfc2f9a40f6d5
record_format Article
spelling doaj-e3f32ee024af465f8b1bfc2f9a40f6d52020-11-24T20:51:04ZengDove Medical PressDrug Design, Development and Therapy1177-88812015-10-012015default5595560024107Urinary kallidinogenase for the treatment of cerebral arterial stenosisZhao LZhao YWan QZhang HLiandong Zhao,1,2 Ying Zhao,2 Qi Wan,1 Haijun Zhang3 1Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 2Department of Neurology, The Second People’s Hospital of Huai’an and The Affiliated Huai’an Hospital of Xuzhou Medical College, Huai’an, Jiangsu, 3Department of Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, People’s Republic of China Aim: Urinary kallidinogenase (UK) has shown promise in improving cerebral perfusion. This study aimed to examine how UK affects cognitive status and serum levels of amyloid betas (Aβs) 1-40 and 1-42 in patients with cerebral arterial stenosis.Methods: Ninety patients with cerebral arterial stenosis were enrolled, of whom 45 patients received UK + conventional treatment (UK group), and 45 patients received conventional treatment alone as control group. Cognitive status and Aβ1-40 and Aβ1-42 serum levels were determined before treatment and at 4 weeks and 8 weeks after treatment.Results: At 4 weeks after treatment, cognitive status in patients treated with UK clearly improved accompanied by Aβ1-40 serum levels decreasing while there was no change of Aβ1-42. Cognitive status in patients receiving UK continued to improve, Aβ1-40 serum levels declined further as well as Aβ1-42 serum levels began to decrease dramatically at 8 weeks after treatment.Conclusion: UK could improve cognitive status and decrease both Aβ1-40 and Aβ1-42 serum levels to prevent ischemic cerebral injury, which represents a good option for patients with cerebral arterial stenosis.Keywords: urinary kallidinogenase, arterial stenosis, Alzheimer’s disease, Aβ1-40, Aβ1-42https://www.dovepress.com/urinary-kallidinogenase-for-the-treatment-of-cerebral-arterial-stenosi-peer-reviewed-article-DDDT
collection DOAJ
language English
format Article
sources DOAJ
author Zhao L
Zhao Y
Wan Q
Zhang H
spellingShingle Zhao L
Zhao Y
Wan Q
Zhang H
Urinary kallidinogenase for the treatment of cerebral arterial stenosis
Drug Design, Development and Therapy
author_facet Zhao L
Zhao Y
Wan Q
Zhang H
author_sort Zhao L
title Urinary kallidinogenase for the treatment of cerebral arterial stenosis
title_short Urinary kallidinogenase for the treatment of cerebral arterial stenosis
title_full Urinary kallidinogenase for the treatment of cerebral arterial stenosis
title_fullStr Urinary kallidinogenase for the treatment of cerebral arterial stenosis
title_full_unstemmed Urinary kallidinogenase for the treatment of cerebral arterial stenosis
title_sort urinary kallidinogenase for the treatment of cerebral arterial stenosis
publisher Dove Medical Press
series Drug Design, Development and Therapy
issn 1177-8881
publishDate 2015-10-01
description Liandong Zhao,1,2 Ying Zhao,2 Qi Wan,1 Haijun Zhang3 1Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 2Department of Neurology, The Second People’s Hospital of Huai’an and The Affiliated Huai’an Hospital of Xuzhou Medical College, Huai’an, Jiangsu, 3Department of Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, People’s Republic of China Aim: Urinary kallidinogenase (UK) has shown promise in improving cerebral perfusion. This study aimed to examine how UK affects cognitive status and serum levels of amyloid betas (Aβs) 1-40 and 1-42 in patients with cerebral arterial stenosis.Methods: Ninety patients with cerebral arterial stenosis were enrolled, of whom 45 patients received UK + conventional treatment (UK group), and 45 patients received conventional treatment alone as control group. Cognitive status and Aβ1-40 and Aβ1-42 serum levels were determined before treatment and at 4 weeks and 8 weeks after treatment.Results: At 4 weeks after treatment, cognitive status in patients treated with UK clearly improved accompanied by Aβ1-40 serum levels decreasing while there was no change of Aβ1-42. Cognitive status in patients receiving UK continued to improve, Aβ1-40 serum levels declined further as well as Aβ1-42 serum levels began to decrease dramatically at 8 weeks after treatment.Conclusion: UK could improve cognitive status and decrease both Aβ1-40 and Aβ1-42 serum levels to prevent ischemic cerebral injury, which represents a good option for patients with cerebral arterial stenosis.Keywords: urinary kallidinogenase, arterial stenosis, Alzheimer’s disease, Aβ1-40, Aβ1-42
url https://www.dovepress.com/urinary-kallidinogenase-for-the-treatment-of-cerebral-arterial-stenosi-peer-reviewed-article-DDDT
work_keys_str_mv AT zhaol urinarykallidinogenaseforthetreatmentofcerebralarterialstenosis
AT zhaoy urinarykallidinogenaseforthetreatmentofcerebralarterialstenosis
AT wanq urinarykallidinogenaseforthetreatmentofcerebralarterialstenosis
AT zhangh urinarykallidinogenaseforthetreatmentofcerebralarterialstenosis
_version_ 1716802835540082688